Key points are not available for this paper at this time.
As countries and health care providers rush to create huge new databases linked to genetic data (see main text), an increasing number of companies in the United States are amassing large, entirely private, “biobanks” of DNA and tissue samples. The companies either use this material themselves or sell it to drug companies or academic researchers for studying diseases, say, or tailoring drugs to individuals.
Jocelyn Kaiser (Fri,) studied this question.